Milestone Pharmaceuticals is trading at $0.87 (-5.02%), with broader risk-off sentiment likely contributing.
- On September 23, 2026, no fresh company-specific announcement was identified.
- Recent coverage remains focused on its earlier China approval for etripamil.
- Major U.S. indexes are lower amid rising oil prices, Treasury yields, inflation concerns, and geopolitical uncertainty.